Showing 4771-4780 of 7317 results for "".
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- La Roche-Posay Launches New Dark Spot Serumhttps://practicaldermatology.com/news/la-roche-posay-launches-dark-spot-serum/2462254/La Roche-Posay, a subsidiary of L'oreal, recently announced the launch of its new a new serum corrector for dark spots, the Mela B3 Dark Spot Serum with MelasylTM + Nicinamide. According to the manufacturer, the launch was preceded by 18 years of research, as well as rese
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://practicaldermatology.com/news/galderma-announces-filing-recepetion-for-investigational-prurigo-nodularis-treatment/2462243/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The agency, according to a news
- Six Dermatology Biotechs Combine to Form Alys Pharmaceuticalshttps://practicaldermatology.com/news/six-dermatology-biotechs-combine-to-form-alys-pharmaceuticals/2462241/Originating from the aggregation of six asset-centric dermatology companies, Alys Pharmaceuticals was launched with $100 million financing by Medicxi, a healthcare-focused investment firm. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharma
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- YCANTH Receives Permanent J-Code Status from CMShttps://practicaldermatology.com/news/ycanth-receives-permanent-j-code-from-cms/2462230/The Centers for Medicare and Medicaid Services (CMS) have granted a permanent J-code (J7354) for YCANTH, the only FDA-approved treatment for molluscum contagiosum.
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode